TY - JOUR
T1 - Phase I studies of continuous-infusion paclitaxel given with standard aggressive radiation therapy for locally advanced solid tumors
AU - Rosenthal, D. I.
AU - Close, L. G.
AU - Lucci, J. A.
AU - Schold, S. C.
AU - Truelson, J.
AU - Fathallah-Skaykh, H.
AU - Kamen, B.
AU - Vultch, F. M.
AU - Gazdar, A. F.
AU - Griener, J.
AU - Landay, M.
AU - Mendelsohn, D.
AU - Tourville, J.
AU - Rogers, P.
AU - Orr, K. Y.
AU - McWhorter, J.
AU - Carbone, D. P.
PY - 1995
Y1 - 1995
N2 - Currently available therapies are unsatisfactory for locally advanced solid tumors of the lung, head and neck, and brain. Laboratory data suggest that the addition of paclitaxel (Taxol; Bristol-Myers Squibb Oncology, Princeton, NJ), a microtubule-stabilizing drug, to radiation therapy may result in significant radiation sensitization, perhaps because paclitaxel induces cell cycle arrest at G2/M. Relatively low concentrations, 1 to 10 nmol/L, appear to be optimal for direct cytotoxicity and radiosensitization in vitro. Within this dose range, more prolonged exposure seems to result in higher response rates. We are conducting phase I trials designed to test continuous infusion (24 hours per day, 7 days per week) intravenous paclitaxel combined with standard curative-intent radiation therapy. To date, 22 patients are evaluable, and the maximum tolerated dose of paclitaxel has not been reached at up to 2.5 mg/m2/d. Observed toxicities include anemia, lymphopenia, mucositis, and cutaneous erythema/desquamation.
AB - Currently available therapies are unsatisfactory for locally advanced solid tumors of the lung, head and neck, and brain. Laboratory data suggest that the addition of paclitaxel (Taxol; Bristol-Myers Squibb Oncology, Princeton, NJ), a microtubule-stabilizing drug, to radiation therapy may result in significant radiation sensitization, perhaps because paclitaxel induces cell cycle arrest at G2/M. Relatively low concentrations, 1 to 10 nmol/L, appear to be optimal for direct cytotoxicity and radiosensitization in vitro. Within this dose range, more prolonged exposure seems to result in higher response rates. We are conducting phase I trials designed to test continuous infusion (24 hours per day, 7 days per week) intravenous paclitaxel combined with standard curative-intent radiation therapy. To date, 22 patients are evaluable, and the maximum tolerated dose of paclitaxel has not been reached at up to 2.5 mg/m2/d. Observed toxicities include anemia, lymphopenia, mucositis, and cutaneous erythema/desquamation.
UR - http://www.scopus.com/inward/record.url?scp=0029023011&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029023011&partnerID=8YFLogxK
M3 - Article
C2 - 7644923
AN - SCOPUS:0029023011
SN - 0093-7754
VL - 22
SP - 13
EP - 17
JO - Seminars in oncology
JF - Seminars in oncology
IS - 4 SUPPL. 9
ER -